Orwin John A
SEC-identified person · CIK 1477384 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Anaptysbio, INC ANAB | Director | filed 2023 - 2026 |
| First Tracks Biotherapeutics, Inc. TRAX | Director | filed 2026 - 2026 |
| Travere Therapeutics, Inc. TVTX | Director | filed 2017 - 2026 |
| Cargo Therapeutics, Inc. CRGX | Director | filed 2023 - 2025 |
| Atreca, Inc. BCEL | Director · President & CEO | filed 2019 - 2024 |
| Seagen Inc. SGEN | Director | filed 2014 - 2023 |
| Array Biopharma INC ARRY | Director | filed 2012 - 2019 |
| Relypsa Inc RLYP | Director · President & CEO | filed 2013 - 2016 |
| Affymax INC AFFY | Director · President and COO | filed 2010 - 2013 |
| Neurogesx Inc NGSX | Director | filed 2009 - 2012 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.